$EVFM – Evofem Biosciences, Inc., promotional campaign starting Jul 19, 2022 @ 11:20 AM CST

on July 19, 2022 Stock Promotion Tracking and Tags: , , , , , , , , , with 0 comments

Summary

Start time:
11:20 AM
Start date:
July 19, 2022
Symbol:
EVFM
Company:
Evofem Biosciences, Inc.
Stock promoter:
"OTC Stock Review"
Stock promoter rank:
18 out of 25
Promoter score:
8.1
Campaign ID:
37354

Evofem Biosciences, Inc.

Market capitalization:
$80,510,049
(as of August 30, 2021)
Website:
Outstanding shares:
102,835,674
(as of April 30, 2021)

Stock Promoter Performance

The following charts displays the first day results for campaigns by "OTC Stock Review". Results are taken from a total of 19 stock promotions by this stock promoter that have been tracked by OTC Dynamics.
42% closed down

42% closed up

15% had no net effect

Last 3 Stock Promotions By "OTC Stock Review"

Symbol Company Start Date Close Change
CBNT C-Bond Systems Inc. June 21, 2022 0.014 4%
SLDX STELLA DIAGNOSTICS INC. June 16, 2022 0.290 -17%
NUGL NUGL, Inc. June 16, 2022 0.053 14%

EVFM Promotional Newsletter

The following is a newsletter released by "OTC Stock Review" promoting Evofem Biosciences, Inc.

Caution

The following newsletter has not been verified for accuracy or completeness.

OTC Stock Review Award Winning Small Cap Stock Picks Since 2004

Evofem Biosciences

Dear

EVFM has traded almost 2 billion shares in the past month. The stock went from the low $0.30's to $1.50 as investors digested the impact the Supreme Court's Roe vs Wade decision would have on women's health companies. As of June 30, there are 17.5 million shares showing as short interest. Who knows what the real number is The July 15 short interest numbers should be coming out soon. This company is well funded and has cash. No dilution for a capital raise is coming anytime soon. In the past week the shorts have pushed the stock lower, but the fundamentals of EVFM say they won't be able to keep it down. If you're looking for a great little company to trade, check out EVFM.

Evofem Biosciences, Inc. NASDAQ EVFM makes Phexxi, the first FDA-approved, hormone-free, on-demand prescription contraceptive vaginal gel method of birth control used for the prevention of pregnancy. Phexxi comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is FDA approved and currently on the market. In the first quarter of fiscal 2022, there were 27,053 units dispensed, which resulted in net product sales of $4.3 million, which was a 19% increase from the previous quarter.

Already approved by the FDA as a contraceptive, Phexxi is also in development for two potential new indications, which include the prevention of chlamydia and gonorrhea in women. In March 2022, Evofem completed enrollment in EVOGUARD, the confirmatory Phase 3 clinical trial to evaluate the safety and efficacy of Phexxi for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. Top-line results are expected in the second half of 2022.

EVO100 has been granted Fast Track Designation for the prevention of chlamydia in women and the prevention of gonorrhea in women and is designated a Qualified Infectious Disease Product QIDP for both indications by the U.S. Food and Drug Administration.
Two analysts adjusted their price targets. Both are much higher than where the stock trades today.

Six reasons to buy EVFM right now
Evofem increased Phexxi net product sales 19% to $4.3 million for the first quarter of 2022 vs. fourth quarter 2021.
Evofem reduced its selling and marketing costs by 49% and its total operating expense by 19%.
The stock has been crushed, is trading at half of 2022 sales estimates, is trading in oversold territory on the MACD, and there's probably a huge short position that will be covering soon
Evofem received confirmation three weeks ago from one of the largest Pharmacy Benefit Managers PBMs in the nation that they will add Phexxi to their national template formularies with no restrictions. PBMs are companies that manage prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers, and other payers. Three large PBMs CVS, Express Scripts, and UnitedHealth's Optum account for more than 70 percent of claims volume.
Great news coming from the Affordable Care Act
Another vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women is coming soon It has been Fast Tracked by the FDA

Check out this interview with Evofem Bioscience CEO, Saundra Pelletier .
Also, here is who is changing women's health forever.
Evofem Bioscience website
Phexxi website
Evofem Bioscience Investor Overview
Phexxi - The First and Only Hormone-Free, On-Demand Prescription Contraceptive Vaginal Gel

In the interest of getting you timely information, this is copied directly from . I encourage you to do some more research. Phexxi vaginal gel provides women an in-the-moment contraceptive that can be easily applied 0-60 minutes before each act of intercourse and works by maintaining the baseline vaginal pH environment.

Baseline vaginal pH levels can range from 3.5 to 4.5. When semen enters the vagina, it raises the vaginas pH level, which allows sperm to be mobile and swim up the reproductive canal. Phexxi works to keep vaginal pH in the baseline range of 3.5 to 4.5, which lowers sperm mobility, lowering the chance of sperm reaching the egg.

Women should not have to rely on a daily ritual, their partner, an invasive procedure, or an injection from their physician to protect themselves from unwanted pregnancy. Many women seek a safe, FDA-approved localized method of birth control that does not require the introduction of hormones into their bodies.

Because Phexxi is a non-hormonal birth control, it is not associated with side effects like depression, mood swings and irritability. Taking hormones may not be right for some women, especially for those with certain medical conditions including clotting disorders and most cancers, limiting their birth control options.

Phexxi provides a hormone-free contraceptive option for women who cannot or do not want to use a hormonal contraceptive as their birth control method. Phexxi is the hormone-free birth control women have been waiting for.

Proven Safe and Effective

Phexxi is 93% effective at preventing pregnancy when used as directed by a healthcare provider.

Phexxi is 86% effective with typical use typical use includes women who may not have correctly followed the Instructions for Use during the clinical trial.

2011 Affordable Care Act Free Birth Control

This is not being enforced, but it will be on January1, 2023. This is going to be a big win for EVFM

In 2011, President Obama signed the birth control mandate into law as part of the Affordable Care Act ACA. Since the birth control mandate came into effect, the number of women with out-of-pocket expenses towards contraceptives dropped from 21% to 3%. What most people understand about the mandate is that .

Before the birth control mandate passed, women were required to pay out-of-pocket costs for birth control alongside their health insurance premium and yearly deductible. After the birth control mandate was signed into law, women in the United States no longer had to pay those out-of-pocket costs, as the ACA required insurance companies to cover contraceptive methods and counseling even if they hadnt met their deductibles.

Roe vs. Wade

The , according to a leaked initial draft majority opinion written by Justice Samuel Alito. Maybe it's true, maybe it's not If it is true, FDA-approved contraceptives, like Phexxi, are going to be in big demand.

Chlamydia amd Gonorrhoeae

Evofems pipeline includes programs developing Phexxi for the prevention of two common STIs and EVO200 to reduce recurrent Bacterial Vaginosis BV.

Every day, more than 1 million new cases of sexually transmitted infections STIs are acquired worldwide among people aged 15-49 years.4Every sexually active woman, no matter what form of contraception she is using, is potentially at risk to contract an STI.

In the United States, the CDC estimates that 4.0 million and 1.6 million new cases of chlamydia and gonorrhea, respectively, occurred in 2018 alone.6 The number of reported cases is lower than the estimated total number because infected people are often unaware of, and do not seek treatment for, their infections. Almost 60% of women infected with chlamydia have no symptoms.7

Chlamydia and gonorrhea have been reported to be responsible for one-third to half of pelvic inflammatory disease PID cases. PID can cause serious, long-term problems including infertility, ectopic pregnancy, and chronic pelvic pain.8

In 2020, Evofem initiated EVOGUARD, a confirmatory Phase 3 clinical trial to evaluate the safety and efficacy of EVO100 the investigational name for Phexxi for the prevention of urogenital transmission of chlamydia and gonorrhea in women. Top-line study results are expected in the second half of 2022.

The U.S. Food and Drug Administration granted EVO100 Phexxi Fast Track designation for the prevention of both chlamydia and gonorrhea. Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs.

Additionally, the FDA has awarded EVO100 Phexxi Qualified Infectious Disease Product QIDP designation for the prevention of both chlamydia and gonorrhea in women. A drug that receives QIDP designation may qualify for an additional five years of marketing exclusivity.

EVOGUARD builds on the positive, statistically significant results of the Companys AMPREVENCE Phase 2b clinical trial. This landmark study met its primary and secondary endpoints, demonstrating a 50% relative risk reduction in chlamydia infection and a 78% relative risk reduction in gonorrhea infection compared to placebo.5 The AMPREVENCE manuscript was published in the prestigious peer-reviewed journal American Journal of Obstetrics and Gynecology in 2021.

Assuming FDA approval for these potential new indications, Phexxi is expected to be the first prescription product approved to address this critical large unmet medical need.

Summary
Evofem increased Phexxi net product sales 19% to $4.3 million for the first quarter of 2022 vs. fourth quarter 2021.
Evofem reduced its selling and marketing costs by 49% and its total operating expense by 19%.
The stock has been crushed and is trading in oversold territory on the MACD. Also, there's probably a huge short position that will be covered soon
Evofem received confirmation three weeks ago from one of the largest Pharmacy Benefit Managers PBMs in the nation that they will add Phexxi to their national template formularies with no restrictions. PBMs are companies that manage prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers, and other payers. Three large PBMs CVS, Express Scripts, and UnitedHealth's Optum account for more than 70 percent of claims volume.
Great news coming from the Affordable Care Act as the government enforces the no deductible on birth control part.
EVFM could get favorable results from the FDA any day on tests for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. EVO100 Phexxi has been Fast Tracked by the FDA

NASDAQ Symbol EVFM

Current Price $0.84

Shares Outstanding

38.7 million

Market Cap $31 million

52 Week Trading Range

52-Week Low $0.33

52-Week High $21.30

Corporate Offices

12400 High Bluff Drive, Suite 600
San Diego, CA 92130

Investor Contact
Amy Raskopf
Vice President of Investor Relations

858.550.1900 Ext. 167

917.673.5775

Website

OTC Stock Review is not registered as an Investment Advisor or a BrokerDealer. The information in this newsletter is not an offer to buy or sell securities of the companies profiled. Information is for informative purposes, not intended as advice for investment and is subject to change without notice. OTC Stock Review has been compensated fifty thousand dollars to perform investor relations services for evfm. Officers and directors of OTC Stock Review hold a long equity position in evfm and may from time to time trade in these securities for their own accounts. Information on each company is from public releases and can not be guaranteed by OTC Stock Review. Companies profiled herein may carry a high investment risk readers should carefully review profiled companies thoroughly with their investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled companies and reflects the opinion of the author. Readers should obtain copies of the profiled Companys periodic reports filed with the United States Securities and Exchange Commission, generally available at or .

If you no longer wish to receive these emails, please reply to this message with Unsubscribe in the subject line or simply click on the following link

OTC Stock Review
3455 Peachtree Rd. N.E.
5th Floor
Atlanta, Georgia 30328
US

the marketing policy.

Get Every Penny Stock Alert!

OTC Dynamics tracks all penny stock promotions. Become a member today and never miss another penny stock promotion!

Sign up today!

Note

OTC Dynamics is not affiliated with the company being promoted or the associated stock promoter.

The information on this page is not a recommendation to buy or sell securities.